The company pled guilty to one misdemeanor charge and paid a fine of $15 million. As a result, the department of justice dismissed 13 felony charges against the company. The company was charged with marketing unapproved products for human bone growth, according to Bloomberg Businessweek news report.
Stryker’s misbrand may have led surgeons to combine the company’s OP-1 and OP-1 Putty with bone filler Calstrux, which could have adverse events.
Related Articles on Orthopedic Devices:
Zyga Technology Names Jim Bullock President & CEO
Zimmer Acquires Synvasive Technology
VG Innovations Releases Spine Device for Low Back Pain
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
